Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EVRI (BMS-690514)
EVRI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EVRI (BMS-690514) | DRUG | Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay |
Inclusion Criteria: * Healthy male subjects * Body mass index (BMS) of 18 - 30 kg/m², inclusive Exclusion Criteria: * Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
EVRI is an investigational small molecule developed by Bristol-Myers Squibb for cancer. It is also known as BMS-690514. EVRI has been studied in a Phase 1 clinical trial and is not approved for any indication. The compound was evaluated in a pharmacokinetics and metabolism study in healthy male subjects.
EVRI is being developed for the treatment of cancer. It is an investigational agent and has not been approved for any use. The only clinical trial of EVRI listed was conducted in healthy male volunteers to study how the drug is processed in the body, not to treat patients.
EVRI is made by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb is the developer of EVRI, also known as BMS-690514.
EVRI is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 program for EVRI has been completed.
EVRI has been studied in one clinical trial, NCT00578916, titled Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects. The trial was a completed Phase 1 study that enrolled 17 healthy male volunteers in Switzerland. No active trials of EVRI are ongoing.
Yes, EVRI is also known as BMS-690514. Bristol-Myers Squibb developed the compound under the designation BMS-690514, and EVRI is an alternative name for the same investigational small molecule being studied in cancer.